AVANT GARDE-TIMI 43 was a proof of concept trial to evaluate the efficacy of early RAAS inhibition with aliskiren (a renin antagonist), valsartan, or their combination in lowering natriuretic peptides in patients with acute coronary syndromes.
Patients with acute coronary syndromes and elevated levels of natriuretic peptides: the results of the AVANT GARDE-TIMI 43 Trial
Eur Heart J. 2010 Aug;31(16):1993-2005.
Inhibition of Renin-Angiotensin System (RAS) Reduces the Rise in Plasma Aldosterone Levels After Acute Coronary Syndromes in Patients with Preserved Left Ventricular Function: Insight From AVANT GARDE-TIMI 43 Trial. Clin Chem. 2013 Jun;59(6):959-67.